Clinical bottom line
Refractory nocturnal enuresis (NE) in adults remains a challenging condition with limited high-quality evidence guiding novel therapeutic options. Emerging treatments such as neuromodulation show potential efficacy and safety, particularly for patients unresponsive to conventional therapies like desmopressin and alarms. However, most data derive from pediatric populations or small adult cohorts, necessitating cautious extrapolation. Multimodal approaches combining pharmacologic and neuromodulatory strategies may improve outcomes but require further validation in adult refractory NE (Chuang et al., 2014; Jabbour et al., 2019).
What the evidence shows
Nocturnal enuresis in adults is often underrecognized and may share pathophysiological mechanisms with pediatric cases, including bladder dysfunction and impaired arousal (Chen et al., 2026). Traditional first-line therapies—desmopressin, enuresis alarms, and behavioral interventions—show variable efficacy, with a subset of patients remaining refractory.
Chuang et al. (2014) highlight neuromodulation as a promising novel therapy targeting neural pathways involved in bladder control. Their review suggests that techniques such as posterior tibial nerve stimulation and sacral neuromodulation can reduce enuretic episodes with favorable safety profiles, though adult-specific data are sparse.
Jabbour et al. (2019) report on a novel therapeutic strategy combining pharmacologic agents with behavioral therapy, demonstrating higher efficacy in primary nocturnal enuresis. While focused on pediatric patients, these findings may inform adult treatment paradigms.
Older pharmacologic studies (Schmitt et al., 1990) provide foundational safety data for drugs used in NE, but newer agents and combinations require updated evaluation.
Caveats and uncertainty
Most robust data pertain to children; adult-specific trials are limited.
Heterogeneity in definitions, outcome measures, and treatment protocols complicates comparisons.
Long-term safety and durability of novel therapies in adults remain unclear.
Potential placebo effects and psychosocial factors require consideration.
Neuromodulation accessibility and cost may limit widespread adoption.
How this may change practice
Clinicians managing refractory adult NE should consider multidisciplinary evaluation including urodynamic studies to identify underlying dysfunction.
Neuromodulation may be offered as adjunctive therapy in specialized centers, particularly when conventional treatments fail.
Combination therapies tailored to individual patient profiles could enhance response rates.
Ongoing research and clinical trials in adults are needed to establish evidence-based guidelines.
Patient education on realistic expectations and adherence remains critical.